Breast cancer Cancer Malignant neoplasm of breast
Conditions
Interventions
This prospective cohort study will recruit patients from the Department of Clinical Oncology in Prince of Wales Hospital in Hong Kong. Self-reported endocrine symptoms and the saliva of patients will
Sponsors
The Chinese University of Hong Kong
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Chinese women?with histologically confirmed estrogen receptor-positive, stage I–III, primary invasive breast cancer 2. Treated with definitive surgery and/or chemotherapy and started on tamoxifen (20 mg daily) within the past month
Exclusion criteria
Exclusion criteria: 1. Patients with other primary malignancies within the last 5 years 2. Patients who are pregnant or are planning to become pregnant, lactating 3. Treated with investigational drugs within the 4 weeks prior to enrolment 4. Not able to provide informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Endocrine symptoms measured using the Greene Climacteric Scale (GCS) and the Functional Assessment of Cancer Therapy-Endocrine subscale (FACT–ES) questionnaire (version 4) at enrolment, 3, 6, 9, 12, 15 and 18 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug adherence measured using the Modified Medication Adherence Report Scale (MMARS) and the Medication Possession Ratio (MRP) at 3, 6, 9, 12, 15 and 18 months | — |
Countries
Hong Kong
Outcome results
None listed